Gonadorelin
Synthetic GnRH (1-10). Stimulates pituitary LH and FSH release. Used clinically in fertility and TRT-axis maintenance.
Originally FDA-approved as Factrel for diagnostic/fertility use (withdrawn from US market 2019 for commercial reasons). Now produced via 503A compounding, increasingly common in TRT clinics as an HCG alternative for testicular volume preservation. Pulsatile dosing matches endogenous GnRH; sustained dosing causes receptor desensitization (the basis of GnRH-agonist cancer therapy).
Pulsatile dosing only — sustained dosing produces opposite effect. Compounded gonadorelin quality varies; verify pharmacy accreditation.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- BModerate evidence
Gonadorelin — primary mechanism: synthetic gnrh (1-10). stimulates pituitary lh and fsh release. used clinically in fertility and trt-axis maintenance.
1 supporting referencesVerified 5d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 100-300 µg · 2-3x weekly, subcutaneous
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
FDA Cat. 1 — compounding (Factrel withdrawn 2019)